IDDI appoints Linda Danielson as its new Chief Executive Officer
Ottignies, BELGIUM, December 6, 2022 – International Drug Development Institute (IDDI), a privately held, expert biostatistical and clinical data services provider in the field of clinical research based in Belgium, with offices in Raleigh, NC, USA, today announced the appointment of Linda Danielson as the Company’s new Chief Executive Officer (CEO), effective January 1, 2023. She succeeds Damien Tremolet, CEO since 2009, who will continue to serve as Executive Chairman of the Board of IDDI.
Linda Danielson holds an M.S. in Biostatistics from the University of Wisconsin-Madison. She joined IDDI in 2006 as Statistical Advisor. She became Chief Operating Officer (COO) in 2011 and Executive Vice-President (VP), IDDI Inc. in 2016. Ms. Danielson has been key in the operational development of the company, including its US branch in Raleigh, North Carolina. Prior to joining IDDI, she served for many years as Head of Biostatistics at UCB Pharma in Belgium.
After 13 years of successful development of IDDI, Mr. Tremolet said it was the right time for him to make way for new leadership while continuing to support the company as Executive Chairman of the Board.
“Linda’s wealth of highly-relevant managerial and operational expertise increases the breadth of strategic leadership and operational excellence at IDDI. She will help us strengthen our unique offering of advanced biostatistics and innovative integrated RTSM and CDM services among our clients in the USA and Europe. We are confident that under her leadership we will further enhance the value we deliver to our customers, employees, and the life science industry”, said Dr. Marc Buyse, IDDI’s founder and Chief Scientific Officer.
“I am thrilled and honored to be appointed as CEO of IDDI and I am very excited to be leading IDDI during the next phase of its evolution” Ms. Danielson said. “The company has grown exponentially over the last few years thanks to the expertise of our staff and the quality of the services delivered. We plan on carefully accelerating our growth in the next years with further investment in our people and the development of novel statistical methods.”
Founded in 1991, IDDI is an expert clinical data services and high-level strategic consulting provider, providing agile clinical trials services for pharmaceutical, biotech, and medical device/diagnostic companies in several disease areas, including oncology and ophthalmology. IDDI optimizes the clinical development of drugs, biologics, and devices thanks to proven statistical expertise and operational excellence. IDDI is headquartered in Brussels, Belgium, with US operations in Raleigh North Carolina.